|Bid||96.93 x 900|
|Ask||96.95 x 800|
|Day's Range||96.49 - 97.20|
|52 Week Range||79.98 - 105.61|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||25.14|
|Forward Dividend & Yield||3.50 (3.61%)|
|Ex-Dividend Date||Mar 09, 2023|
|1y Target Est||112.75|
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. The FDA has determined that the risk of T-cell malignancies applies to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T-cell immunotherapies. Since 2017, six CAR T-cell therapies have been approved by the FDA:
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.